159 related articles for article (PubMed ID: 34055227)
1. Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor.
Huestis MP; Durk MR; Eigenbrot C; Gibbons P; Hunsaker TL; La H; Leung DH; Liu W; Malek S; Merchant M; Moffat JG; Muli CS; Orr CJ; Parr BT; Shanahan F; Sneeringer CJ; Wang W; Yen I; Yin J; Rudolph J; Siu M
ACS Med Chem Lett; 2021 May; 12(5):791-797. PubMed ID: 34055227
[TBL] [Abstract][Full Text] [Related]
2. Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3
Huestis MP; Dela Cruz D; DiPasquale AG; Durk MR; Eigenbrot C; Gibbons P; Gobbi A; Hunsaker TL; La H; Leung DH; Liu W; Malek S; Merchant M; Moffat JG; Muli CS; Orr CJ; Parr BT; Shanahan F; Sneeringer CJ; Wang W; Yen I; Yin J; Siu M; Rudolph J
J Med Chem; 2021 Apr; 64(7):3940-3955. PubMed ID: 33780623
[TBL] [Abstract][Full Text] [Related]
3. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
Yen I; Shanahan F; Merchant M; Orr C; Hunsaker T; Durk M; La H; Zhang X; Martin SE; Lin E; Chan J; Yu Y; Amin D; Neve RM; Gustafson A; Venkatanarayan A; Foster SA; Rudolph J; Klijn C; Malek S
Cancer Cell; 2018 Oct; 34(4):611-625.e7. PubMed ID: 30300582
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
[TBL] [Abstract][Full Text] [Related]
7. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel spiro compound as RAF kinase inhibitor with in vitro potency against KRAS mutant cancer.
Zhao P; Wang X; Zhuang L; Huang S; Zhou Y; Yan Y; Shen R; Zhang F; Li J; Hu Q; Liu S; Zhang R; Dong P; Wan H; Bai C; He F; Tao W
Bioorg Med Chem Lett; 2022 May; 63():128666. PubMed ID: 35276360
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Hatzivassiliou G; Haling JR; Chen H; Song K; Price S; Heald R; Hewitt JF; Zak M; Peck A; Orr C; Merchant M; Hoeflich KP; Chan J; Luoh SM; Anderson DJ; Ludlam MJ; Wiesmann C; Ultsch M; Friedman LS; Malek S; Belvin M
Nature; 2013 Sep; 501(7466):232-6. PubMed ID: 23934108
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
15. AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
Flemington V; Davies EJ; Robinson D; Sandin LC; Delpuech O; Zhang P; Hanson L; Farrington P; Bell S; Falenta K; Gibbons FD; Lindsay N; Smith A; Wilson J; Roberts K; Tonge M; Hopcroft P; Willis SE; Roudier MP; Rooney C; Coker EA; Jaaks P; Garnett MJ; Fawell SE; Jones CD; Ward RA; Simpson I; Cosulich SC; Pease JE; Smith PD
Mol Cancer Ther; 2021 Feb; 20(2):238-249. PubMed ID: 33273059
[TBL] [Abstract][Full Text] [Related]
16. Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.
Zhao P; Zhuang L; Wang X; Huang S; Wu H; Zhou Y; Yan Y; Zhang F; Shen R; Li J; Liu S; Zhang R; Dong P; Mao Y; Fan Y; He C; Sun J; Zhang L; Hu Q; Wan H; Feng J; Bai C; He F; Tao W
Eur J Med Chem; 2022 Jan; 228():114040. PubMed ID: 34906761
[TBL] [Abstract][Full Text] [Related]
17. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
18. Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
Nishiguchi GA; Rico A; Tanner H; Aversa RJ; Taft BR; Subramanian S; Setti L; Burger MT; Wan L; Tamez V; Smith A; Lou Y; Barsanti PA; Appleton BA; Mamo M; Tandeske L; Dix I; Tellew JE; Huang S; Mathews Griner LA; Cooke VG; Van Abbema A; Merritt H; Ma S; Gampa K; Feng F; Yuan J; Wang Y; Haling JR; Vaziri S; Hekmat-Nejad M; Jansen JM; Polyakov V; Zang R; Sethuraman V; Amiri P; Singh M; Lees E; Shao W; Stuart DD; Dillon MP; Ramurthy S
J Med Chem; 2017 Jun; 60(12):4869-4881. PubMed ID: 28557458
[TBL] [Abstract][Full Text] [Related]
19. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
[No Abstract] [Full Text] [Related]
20. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
